5-AMINO-1MQ - 50mg

Overview

5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic, cell-permeable small molecule investigated as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in the methylation of nicotinamide and regulation of NAD+ availability. It is classified as a research compound and is not FDA-approved. Current evidence is primarily derived from preclinical cell-based and animal studies.

Mechanism of Action

By inhibiting NNMT, 5-Amino-1MQ preserves intracellular NAD+ levels by preventing the conversion of nicotinamide to 1-methylnicotinamide (1-MNA). Elevated NAD+ availability activates SIRT1 (sirtuin-1) pathways associated with mitochondrial biogenesis, fat oxidation, and metabolic flexibility. Simultaneously, higher S-adenosylmethionine (SAM) availability supports methylation-dependent gene expression and epigenetic regulation.

Research and Off-Label Applications

Investigated for reduction of visceral and white adipose tissue, improved insulin sensitivity and glucose metabolism, preservation of lean muscle mass, enhancement of mitochondrial function and energy expenditure, and muscle strength and recovery support. A 2024 preclinical study published in Scientific Reports demonstrated additive improvements in grip strength and exercise endurance when combined with resistance training in aged mice.

Administration

Research protocols use oral dosing of approximately 50 mg taken 1–3 times daily, or subcutaneous injection. Common research cycles are approximately 2 months on, followed by a 1-month washout period.

Potential Adverse Effects

Generally well tolerated in available studies. Reported mild effects include nausea, fatigue, and dizziness. Long-term human safety data is not established.